Wells Fargo & Company MN increased its position in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) by 55.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,207,069 shares of the medical research company’s stock after acquiring an additional 432,449 shares during the period. Wells Fargo & Company MN owned approximately 1.90% of PRA Health Sciences worth $91,943,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of PRAH. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in PRA Health Sciences by 12.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after acquiring an additional 160 shares during the period. Carroll Financial Associates Inc. increased its holdings in PRA Health Sciences by 127.4% during the 3rd quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock worth $112,000 after acquiring an additional 790 shares during the period. CAPROCK Group Inc. bought a new stake in PRA Health Sciences during the 2nd quarter worth approximately $208,000. Comerica Bank bought a new stake in PRA Health Sciences during the 3rd quarter worth approximately $214,000. Finally, Trustmark National Bank Trust Department bought a new stake in PRA Health Sciences during the 2nd quarter worth approximately $225,000. 98.49% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director Matthew P. Young sold 5,115 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $79.90, for a total value of $408,688.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.10% of the stock is currently owned by corporate insiders.

A number of research firms recently weighed in on PRAH. Robert W. Baird set a $94.00 target price on shares of PRA Health Sciences and gave the stock a “buy” rating in a report on Friday, December 1st. Mizuho set a $87.00 price target on shares of PRA Health Sciences and gave the stock a “buy” rating in a report on Friday, December 1st. KeyCorp reissued a “buy” rating and issued a $93.00 price target (up previously from $86.00) on shares of PRA Health Sciences in a report on Monday, October 30th. SunTrust Banks reissued a “buy” rating and issued a $101.00 price target on shares of PRA Health Sciences in a report on Friday, October 27th. Finally, Credit Suisse Group increased their price target on shares of PRA Health Sciences from $90.00 to $93.00 and gave the stock an “outperform” rating in a report on Thursday, October 26th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $89.09.

PRA Health Sciences, Inc. (NASDAQ PRAH) opened at $81.00 on Wednesday. The company has a market cap of $5,186.81, a price-to-earnings ratio of 30.09, a PEG ratio of 1.42 and a beta of 0.40. PRA Health Sciences, Inc. has a twelve month low of $52.76 and a twelve month high of $84.38. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.03. The firm had revenue of $494.55 million for the quarter, compared to analyst estimates of $477.89 million. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The business’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.64 EPS. equities research analysts expect that PRA Health Sciences, Inc. will post 3.2 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Wells Fargo & Company MN Has $91.94 Million Position in PRA Health Sciences, Inc. (PRAH)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/12/06/wells-fargo-company-mn-has-91-94-million-position-in-pra-health-sciences-inc-prah.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.